TONTARRA MEDIZINTECHNIK acquired by RANTUM CAPITAL

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

Astorg has signed a definitive agreement to acquire Thermo Fisher Scientific's microbiology business, which will become an independent, privately owned platform, backed by Astorg. The transaction consists of a complete corporate carve-out, executed via the Astorg VIII fund, representing the vehicle's tenth investment to date and further concentrating its portfolio exposure within the life sciences sector. The ownership transition is driven by the seller’s strategic decision to divest non-core clinical assets, allowing the parent company to reallocate its corporate capital toward higher-growth molecular diagnostics. For the target company, the separation from a large corporate matrix removes internal budget competition and enables dedicated reinvestment into product innovation. The ownership transition establishes a clear operational mandate focused on scaling global market share, expanding the current commercial infrastructure, and pursuing consolidation via strategic mergers and acquisitions. The post-closing roadmap requires the execution of complex transitional service agreements to ensure continuity across thirteen global manufacturing and research facilities without disrupting ongoing supply contracts. The definitive agreement is subject to customary anti-trust clearances and regulatory approvals, with final closing projected during the second half of 2026.

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading technical operational depth in refraction and finishing with the group’s established leadership in tonometry and imaging. This fusion effectively creates a specialized powerhouse in the ophthalmic arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of diagnostic and optical retail workflows. The operation allows the group to execute a definitive structural expansion of its total addressable market, specifically targeting high-growth segments such as Optical Coherence Tomography (OCT). By incorporating the target's innovative product suite, the organization can now provide a more robust and integrated solution set for professionals across optometry, retail, and ophthalmology.

Devyser Diagnostics AB has finalized the acquisition of CyberGene AB from Level Bio AB. The strategic rationale for this transaction centers on a "portfolio-optimization" play, merging the target's established diagnostic kits in aneuploidy and infertility with the group's global commercial infrastructure and direct sales force. This fusion effectively creates a specialized powerhouse in the reproductive health market, providing the group with the necessary hardware to deepen its customer offering in clinical genetics laboratories. This operation allows Devyser Diagnostics to execute a definitive structural transformation of the target's existing market footprint. By absorbing an asset with a high level of customer acceptance but limited global reach, the organization can now leverage its industrialized R&D and sales machine to drive international scaling. The maneuver optimizes the group's financial profile, with the integration expected to yield immediate improvements in gross profit and consolidated EBIT margins. Ultimately, the partnership solidifies the group’s standing as a primary enabler of high-precision molecular diagnostics, while ensuring the organization remains an agile leader in the rapid evolution of genomic testing standards.

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure. This fusion effectively creates a specialized powerhouse in the advanced therapies arena, providing the organization with the scientific talent and lead investigational asset required to address the increasing demand for cures in drug-resistant mesial temporal lobe epilepsy. his operation allows the group to execute a definitive structural expansion beyond symptomatic treatment into the era of disease-modifying medicine. By incorporating the target's innovative GABAergic cell therapy candidate, which has already received RMAT and PRIME designations, the organization can now provide a more robust and integrated solution set for patients who have exhausted traditional pharmaceutical options.

Halma, a global leader in healthcare technology, has completed the acquisition of 100% of Surgistar’s share capital, further strengthening its ophthalmic instrument capabilities within its Healthcare division. Through this transaction, Halma aims to bring the production of high-precision disposables in-house, helping to better secure its supply chain against external volatility. From an industrial standpoint, the deal is driven by the combination of Surgistar’s automated sharpening technologies with Halma’s clinical and commercial reach, ensuring consistently high-quality cutting performance for demanding ophthalmic teams. Rather than simply expanding capacity, the acquisition is expected to unlock meaningful product synergies by integrating a specialized portfolio of blades and cannulas into Halma’s global direct sales network.

Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology. The strategic rationale for this transaction centers on a "portfolio-synergy" play, merging the target's industry-leading technical operational depth in surgical meshes with the group’s extensive distribution network and established suture division (CHIRMAX). This fusion effectively creates a specialized powerhouse in the European medtech arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of soft tissue repair and urogynecological procedures.

The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities. The strategic rationale for this transaction centers on a "technology-integration" play, merging the target's industry-leading expertise in liquid and semi-solid pharmaceuticals with the group’s established global leadership in the CSDMO sector. This fusion effectively creates a specialized powerhouse in the contract manufacturing arena, providing the organization with the technical operational depth required to address the increasing demand for diverse dosage forms. This operation allows the group to execute a definitive structural expansion of its service portfolio, specifically targeting the pharmaceutical and nutraceutical end-markets. By incorporating the target's innovative production facility, the organization can now provide a more robust and integrated solution set for strategic partners looking for comprehensive development support.

In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period. The transaction is fundamentally designed to facilitate the intergenerational transmission of the family-owned enterprise from founder Jacques Mignot to his son, Diego Mignot, who officially assumes the presidency. The equity syndication is further supported by a comprehensive financing package provided by a broad syndicate of tier-one banking partners. This transaction represents a textbook succession-driven recapitalization, allowing the founding family to secure a seamless leadership transition while onboarding specialized institutional capital to fuel the next phase of value creation. For the incoming and reinvesting financial sponsors, this platform investment offers a highly attractive risk-return profile, backing a proven management team operating within the non-cyclical, high-growth animal health vertical. The injection of strategic support and patient capital will empower Neftys Pharma to aggressively pursue its strategic roadmap, which is anchored around five core value-creation levers: intensifying market penetration across Europe (particularly Eastern Europe), executing geographic expansion into new international territories, launching new vertical services, developing proprietary brands, and deepening integration with flagship laboratory partners.

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation. By integrating Céfiméca’s two production sites, the enlarged group reaches a critical mass of five manufacturing facilities and over 400 employees (combined), significantly enhancing its industrial capacity. The deal aims to improve market competitiveness by reducing lead times and offering a more integrated value chain, transitioning from a traditional supplier role to a strategic partnership model. The integration of Céfiméca’s high-value implant range specifically addresses the group's objective to master both the tools and the permanent devices used in joint and spinal procedures.